skyline ventures glp-1 DietWorks Companion ASCO: Legend scientific founder returns
Description
Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.
Safe, personalized programs designed for lasting success
Peanut Butter Chocolate flavor
Rooted in Nature Backed by Science
Each ingredient is clinically validated to support fat oxidation, blood sugar stability, and appetite control while boosting overall performance
